Cite
HARVARD Citation
Garcia, J. et al. (2014). A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 120 (11), pp. 1647-1655. [Online].